Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients

Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbreteau, Guillaume, Vallée, Audrey, Knol, Anne-Chantal, Théoleyre, Sandrine, Quéreux, Gaelle, Frénard, Cécile, Varey, Emilie, Hofman, Paul, Khammari, Amir, Dréno, Brigitte, Denis, Marc G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409003/
https://www.ncbi.nlm.nih.gov/pubmed/32664549
http://dx.doi.org/10.3390/cancers12071871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409003/
https://www.ncbi.nlm.nih.gov/pubmed/32664549
http://dx.doi.org/10.3390/cancers12071871

Ejemplares similares